Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0B8MS
|
||||
| Former ID |
DND000011
|
||||
| Drug Name |
MEDI-547
|
||||
| Synonyms |
MedImmune, MedImmune/AstraZeneca
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] | Phase 1 | [1] | ||
| Company |
AstraZeneca
|
||||
| Target and Pathway | |||||
| Target(s) | Ephrin type-A receptor 2 | Target Info | [2] | ||
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| PI3K-Akt signaling pathway | |||||
| Axon guidance | |||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| Pathway Interaction Database | EphrinA-EPHA pathway | ||||
| Arf6 signaling events | |||||
| Direct p53 effectors | |||||
| EPHA forward signaling | |||||
| Stabilization and expansion of the E-cadherin adherens junction | |||||
| EPHA2 forward signaling | |||||
| Reactome | EPH-Ephrin signaling | ||||
| EPHA-mediated growth cone collapse | |||||
| EPH-ephrin mediated repulsion of cells | |||||
| WikiPathways | NRF2 pathway | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00796055) Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors. U.S. NationalInstitutes of Health. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1822). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.